From the short-term weight loss effect, Tirzepatide injection VS Ketogenic diets

Tirzepatide, a dual GLP-1 and GIP receptor agonist, is FDA-approved (as Zepbound) for weight loss in obese/overweight individuals. It reduces appetite, slows gastric emptying, and enhances insulin sensitivity, leading to significant weight loss.

Tirzepatide clinical trials demonstrate significant weight loss with Tirzepatide. In SURMOUNT-1, participants achieved up to 20.9% weight loss over 72 weeks, with early data suggesting 5-6% weight loss in the first 6 weeks, based on reports like "It takes time, about 8 to 12 weeks to see a 6% to 8% weight loss in adults using Mounjaro" from Drugs.com.

Ketogenic diets (KDs) that elevate beta-hydroxybutyrate (BHB) promote weight and fat loss.

And, a plausible approach to support muscle anabolism during a hypocaloric KD is the use of exogenous ketone salts (KS), which enhance ketosis while also providing additional sodium and potentially other minerals (e.g., potassium, calcium, magnesium). Oral ingestion of ketone salts consisting of beta-hydroxybutyrate (BHB) and minerals is a safe and effective method of transiently increasing circulating ketones as we and others have shown.

The KD clinical data of firgue 2 showed that its about 7-8 kg weight loss after 6 weeks.

Figure 1: Tirzepatide injection

Figure 2: Ketogenic diets